Advertisement
"The Sentinel Principle(TM), our proprietary platform technology for the discovery of blood-based biomarkers, was validated around osteoarthritis, a debilitating joint disease," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This agreement is a positive reflection of the quality of our research and technology and a source of non-dilutive funding that will contribute to our commercialization efforts."
Advertisement
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
About GeneNews --------------
SOURCE GeneNews Limited
